- Home
- CCO vs ABVX Comparison
CCO vs ABVX Comparison
Compare CCO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCO
- ABVX
- Stock Information
- Founded
- CCO 1995
- ABVX 2013
- Country
- CCO United States
- ABVX France
- Employees
- CCO N/A
- ABVX N/A
- Industry
- CCO Advertising
- ABVX
- Sector
- CCO Consumer Discretionary
- ABVX
- Exchange
- CCO Nasdaq
- ABVX Nasdaq
- Market Cap
- CCO 674.9M
- ABVX 401.9M
- IPO Year
- CCO 2005
- ABVX N/A
- Fundamental
- Price
- CCO $1.11
- ABVX $5.86
- Analyst Decision
- CCO Buy
- ABVX Strong Buy
- Analyst Count
- CCO 3
- ABVX 7
- Target Price
- CCO $2.05
- ABVX $37.86
- AVG Volume (30 Days)
- CCO 1.6M
- ABVX 195.8K
- Earning Date
- CCO 05-08-2025
- ABVX 03-24-2025
- Dividend Yield
- CCO N/A
- ABVX N/A
- EPS Growth
- CCO N/A
- ABVX N/A
- EPS
- CCO N/A
- ABVX N/A
- Revenue
- CCO $1,505,230,000.00
- ABVX $9,676,417.00
- Revenue This Year
- CCO $6.23
- ABVX $31.67
- Revenue Next Year
- CCO $4.07
- ABVX $759.77
- P/E Ratio
- CCO N/A
- ABVX N/A
- Revenue Growth
- CCO 4.95
- ABVX 100.87
- 52 Week Low
- CCO $1.18
- ABVX $5.50
- 52 Week High
- CCO $1.88
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- CCO 33.49
- ABVX 39.24
- Support Level
- CCO $1.20
- ABVX $6.01
- Resistance Level
- CCO $1.32
- ABVX $8.47
- Average True Range (ATR)
- CCO 0.07
- ABVX 0.49
- MACD
- CCO -0.01
- ABVX -0.16
- Stochastic Oscillator
- CCO 0.00
- ABVX 11.79
About CCO Clear Channel Outdoor Holdings Inc.
Clear Channel Outdoor Holdings Inc is one of the world's largest outdoor advertising companies. The company is engaged in providing advertising opportunities through billboards, street furniture displays, transit displays, and other out-of-home advertising displays for its clients. Its reportable segment includes America; Airports; Europe-North and Europe-South. The company generates maximum revenue from the America segment. The America segment serves markets throughout the U.S., with over 90% of its revenue generated from billboard displays.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.